On May 5, 2015, Rutgers Cancer Institute of New Jersey was one of seven international sites to offer a clinical trial investigating the surgical removal of the prostate gland (prostatectomy) in addition to as much of the tumor as possible in the surrounding area (debulking) in men newly diagnosed with prostate cancer that has spread to other parts of the body (metastatic).

Results from a previous clinical trial at the Cancer Institute, previously published in the Journal of Translational Medicine), examined two forms of PROSTVAC that provided researchers information on the safety of using this investigational drug.